The Approval Process in Action

Life Sciences Tools & DiagnosticsMedical DevicesRegenerative MedicineBiotechnology / Pharmaceuticals

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

Wedbush Sees Denifanstat as Front-Line Acne Therapy with 249% Upside Potential
Source: Dr. Yun Zhong (05/01/2026)

Wedbush Securities analyst Dr. Yun Zhong reiterated a price target on Sagimet Biosciences (SGMT:NASDAQ), implying roughly 249% upside.

Biotech Co. Finds Massive Physiological Screening Breakthrough
Source: Streetwise Reports (04/29/2026)

MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) files patents for novel voice-biomarker intoxication detection, targeting applications in mining and aviation.

Biopharma Advances High-Impact, First-of-Its-Kind Neuroreparative Drug
Source: Streetwise Reports (04/28/2026)

NervGen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) drug produced sustained neurologic and functional gains in chronic tetraplegia, positioning it for pivotal Phase 3 development.

New York Healthcare Technology Co. Discovers Scalable Behavioral Health Breakthrough
Source: Streetwise Reports (04/28/2026)

DarioHealth Corp.'s (DRIO:NASDAQ) study showed measurable workplace productivity and cognitive function improvements in 1,254 users within weeks, boosting growth potential.

California Biopharma Co. Uncovers Massive Oncology Breakthrough
Source: Streetwise Reports (04/28/2026)

Nurix Therapeutics Inc. (NRIX:NASDAQ) new cancer pipeline data highlights powerful targeted protein degradation advances, with analysts projecting 92% upside potential.